We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Heterogeneity Influences Cancer Immunohistochemistry Results

By LabMedica International staff writers
Posted on 06 Jun 2017
Many gastric cancer (GC) patients are with inoperable lesions and endoscopic biopsy becomes the only available approach to obtain tumor tissues for human epidermal growth factor receptor 2 (HER2) assessment. More...
Unlike resected specimens, biopsy specimens are influenced by many factors and in turn more difficult to manipulate.

Several approaches are available for HER2 status assessment, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and silver in situ hybridization (SISH). Among them, IHC represents an effective and robust test that can be used for most specimens. HER2 assessment in biopsy specimens of gastric cancer (GC) is challenging because of the intratumoral heterogeneity. False negative results may occur because of limited biopsy material.

Pathologists at Fudan University (Shanghai, China) collected 890 biopsy specimens and 459 paired resected specimens from patients who were diagnosed gastric adenocarcinoma by endoscopic biopsy specimens during March 2013 to January 2014. IHC staining of HER2 was performed. HER2 IHC positive (scored 3+) rate was compared based on tumor-containing fragment number, biopsy specimen number, average size and tumor tissue proportion of tumor-containing fragments. The positive predictability of biopsy specimens to resected specimens was analyzed based on tumor fragment number.

The scientists used a HER-2/neu rabbit monoclonal antibody, and the IHC staining was performed in all the cases with Ventana’s iView DAB Detection Kit on their BenchMark XT automated stainer. For each test, small pieces of GC tissue in which HER2 was scored as 3+ and 0 were used in the same slide as positive and negative controls, respectively. Hematoxylin and eosin (HE) sections of all the cases were reviewed by two experienced gastrointestinal pathologists to confirm the diagnosis.

The team found classified 100 patients (11.2%) as HER2 IHC positive (scored 3+), 261 patients (29.3%) were HER2 equivocal (scored 2+). The rest 529 cases were classified as HER2 IHC negative (59.5%), including 289 cases scored 1+ (32.5%) and 240 cases scored 0 (27.0%). In the HER2 IHC positive (scored 3+) patients, 74 cases were intestinal type GCs (74.0%), 10 were diffuse type GCs (10.0%), and the rest 16 belonged to mixed type (16.0%). HER2 IHC positive rates were 2.0%, 3.5%, 7.0%, 13.2%, 17.1%, and 15.9% when tumor fragment numbers were 1, 2, 3, 4, 5 and 6 respectively. HER2 IHC positive rate was not associated with biopsy number, average size of tumor fragments, and tumor tissue proportion of tumor fragments) directly.

The authors concluded that tumor-containing fragment number affects HER2 IHC positive (scored 3+) rate in endoscopic biopsy specimens. Greater than or equal to four tumor fragments give better HER2 IHC positivity and better performance in predicting HER2 status of resected specimens. The study was published on May 26, 2017, in the journal Diagnostic Pathology.

Related Links
Fudan University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.